- Home
- NIO vs JAZZ Comparison
NIO vs JAZZ Comparison
Compare NIO & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIO
- JAZZ
- Stock Information
- Founded
- NIO 2014
- JAZZ 2003
- Country
- NIO China
- JAZZ Ireland
- Employees
- NIO N/A
- JAZZ N/A
- Industry
- NIO Auto Manufacturing
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- NIO Consumer Discretionary
- JAZZ Health Care
- Exchange
- NIO Nasdaq
- JAZZ Nasdaq
- Market Cap
- NIO 7.4B
- JAZZ 7.3B
- IPO Year
- NIO 2018
- JAZZ 2007
- Fundamental
- Price
- NIO $3.54
- JAZZ $108.07
- Analyst Decision
- NIO Hold
- JAZZ Strong Buy
- Analyst Count
- NIO 6
- JAZZ 13
- Target Price
- NIO $5.05
- JAZZ $181.85
- AVG Volume (30 Days)
- NIO 29.8M
- JAZZ 1.3M
- Earning Date
- NIO 06-03-2025
- JAZZ 05-06-2025
- Dividend Yield
- NIO N/A
- JAZZ N/A
- EPS Growth
- NIO N/A
- JAZZ 49.21
- EPS
- NIO N/A
- JAZZ 7.51
- Revenue
- NIO $9,005,433,398.00
- JAZZ $4,064,808,000.00
- Revenue This Year
- NIO $37.90
- JAZZ $5.92
- Revenue Next Year
- NIO $26.13
- JAZZ $4.22
- P/E Ratio
- NIO N/A
- JAZZ $14.39
- Revenue Growth
- NIO 18.18
- JAZZ 5.76
- 52 Week Low
- NIO $3.02
- JAZZ $95.49
- 52 Week High
- NIO $7.71
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- NIO 35.52
- JAZZ 47.97
- Support Level
- NIO $3.63
- JAZZ $106.69
- Resistance Level
- NIO $3.77
- JAZZ $110.48
- Average True Range (ATR)
- NIO 0.11
- JAZZ 3.56
- MACD
- NIO -0.05
- JAZZ 0.55
- Stochastic Oscillator
- NIO 2.67
- JAZZ 68.77
About NIO NIO Inc. American depositary shares each representing one ordinary share
Nio is a leading electric vehicle maker, targeting the premium segment. Founded in November 2014, Nio designs, develops, jointly manufactures, and sells premium smart electric vehicles. The company differentiates itself through continuous technological breakthroughs and innovations such as battery swapping and autonomous driving technologies. Nio launched its first model, its ES8 seven-seater electric SUV, in December 2017, and began deliveries in June 2018. Its current model portfolio includes midsize to large sedans and SUVs. It sold around 222,000 EVs in 2024, accounting for about 2% of the China passenger new energy vehicle market.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.